Boehringer Ingelheim’s obesity asset survodutide faced renewed scrutiny after phase 3 updates at ADA26 showed a notably elevated discontinuation rate due to side effects. The reporting tied discontinuations to the ongoing SYNCHRONIZE-1 program, positioning tolerability as the key talking point alongside efficacy. In parallel, company executives argued that the tolerability profile remains consistent with the class despite the new details shared at the meeting. The coverage also emphasized the efficacy narrative around targeted weight loss, including visceral fat findings from MRI sub-analyses and messaging that weight loss was primarily driven by fat mass. For the market, the juxtaposition of executive reassurance with higher discontinuations reinforces the practical question facing prescribers: whether efficacy gains translate into sustained adherence in long-term obesity treatment.